NCT07416409 2026-02-18
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Completed
Clinical Trials
21 trialsNCT06961331 2026-01-09
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Pfizer
Completed
NCT07009600 2025-06-06
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Completed
NCT05572645 2024-02-26
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Fudan University
Completed
NCT06021379 2023-10-31
AryoTrust® (Trastuzumab) Safety Study
AryoGen Pharmed Co.
Completed
NCT05931042 2023-07-05
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
Rawalpindi Medical College
Completed
NCT01959386 2020-03-03
HerSCin
Hoffmann-La Roche
Completed
NCT00833963 2019-05-16
MotHER
Genentech, Inc.
Completed
NCT01839500 2018-03-29
EVIDENCE
Hoffmann-La Roche
Completed
NCT00875238 2018-02-19
PACE in BC
Vanderbilt University Medical Center
Completed
NCT01152606 2018-01-25
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
Hoffmann-La Roche
Completed
NCT03390608 2018-01-04
Prognostic and Predictive Factors for Small Breast Tumors
Karolinska Institutet
Completed
NCT00755313 2017-11-24
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
University of California, San Francisco
Completed
NCT01480674 2017-08-16
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
Hoffmann-La Roche
Completed
NCT03024450 2017-01-24
Trastuzumab Based Therapy in HER2 Positive AGC
Shanghai Zhongshan Hospital
Completed
NCT02731313 2016-10-28
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
Hoffmann-La Roche
Completed
NCT02658461 2016-04-29
An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)
Hoffmann-La Roche
Completed
NCT00968682 2014-12-31
CADY Study ICORG 08-01
Cancer Trials Ireland
Completed
NCT01077648 2014-05-26
Brain Metastasis in Breast Cancer Patients
GlaxoSmithKline
Completed
NCT00795678 2013-08-02
Chemotherapeutic Agents in Brain/Breast
Case Comprehensive Cancer Center
Completed
NCT01894711 2013-07-10
Real World Efficiency of Trastuzumab in Early Breast Cancer
Maastricht University Medical Center
Completed